ストックスクリーナーアプリを入手
5.45
3.22%
0.17
前日終値:
$5.28
開ける：
$5.3
24時間の取引高:
231.81K
Relative Volume:
0.80
時価総額：
$144.36M
収益：
$832.00K
当期純損益:
$-135.12M
株価収益率:
-8.3846
EPS:
-0.65
ネットキャッシュフロー:
$-124.69M
1週間 パフォーマンス:
-2.68%
1か月 パフォーマンス:
-3.02%
6か月 パフォーマンス:
-52.98%
1年 パフォーマンス:
+21.34%
1日の値動き範囲:
$5.30
$5.5599
1週間の範囲:
$5.25
$5.80
52週間の値動き範囲:
$3.888
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
名前
Inovio Pharmaceuticals Inc
セクター
電話
(858) 410-3134
住所
6769 MESA RIDGE RD., SAN DIEGO, PA
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-09 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-11-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 再開されました | Jefferies | Hold |
| 2021-09-10 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 開始されました | Jefferies | Hold |
| 2021-03-23 | 開始されました | BofA Securities | Neutral |
| 2021-02-12 | 開始されました | Oppenheimer | Outperform |
| 2020-11-17 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2020-11-10 | アップグレード | ROTH Capital | Sell → Neutral |
| 2020-09-28 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-07-01 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2020-06-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2020-05-21 | 開始されました | The Benchmark Company | Buy |
| 2020-04-30 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-03-13 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 開始されました | ROTH Capital | Buy |
| 2018-02-15 | 繰り返されました | Maxim Group | Buy |
| 2017-10-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-06 | 開始されました | Citigroup | Buy |
| 2017-06-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 繰り返されました | Maxim Group | Buy |
| 2017-03-16 | アップグレード | Maxim Group | Hold → Buy |
| 2017-03-16 | ダウングレード | Piper Jaffray | Overweight → Neutral |
すべてを表示
Inovio Pharmaceuticals Inc (INO) 最新ニュース
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock remains steady Wednesday, still outperforms market - MarketWatch
Inovio Pharmaceuticals (LTS:0A43) Probability of Financial Distress (%) : 0.27% (As of Oct. 30, 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $43.80 - MarketBeat
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
Global DNA Nanotechnology Market Future Market Projections: - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Update - MarketBeat
Inovio Pharmaceuticals (LTS:0A43) Change In Prepaid Assets : $-2.12 Mil (TTM As of Jun. 2024) - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011; Promotes Niranjan Y. Sardesai as Chief Operating Officer from Senior Vice President Research and Development - Marketscreener.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Covid-19 Vaccine Market Industry Survey Research Report 2032 – Top Player as Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix – Cauverynews - Cauverynews
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Inovio Pharmaceuticals, Inc. Announces Leadership Appointments - Marketscreener.com
INOVIO Announces Equity Grants for New Employees Under 2022 Inducement Plan - MSN
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $7.00 at Royal Bank of Canada - MarketBeat
INOVIO Reports Inducement Grants Under Inducement Plan - Marketscreener.com
INOVIO to Present at Upcoming Scientific Conferences - Marketscreener.com
Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing - Seeking Alpha
Inovio Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $44.00 Average PT from Analysts - MarketBeat
Inari medical director Hoffman sells over $1.8m in company stock - Investing.com
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
INVO Bioscience (NASDAQ:INVO) Stock Price Down 1.7% - Defense World
INOVIO to Present at Upcoming Scientific Conference - Lelezard
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 - sharewise
Page 2 | INOVIO PHARMACEUTICALS INC Trade Ideas — GETTEX:GBMB - TradingView
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Inovio Pharmaceuticals Inc (INO) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
1.43%
大文字化:
|
ボリューム (24 時間):